Nuformix’s NXP002 data to be presented at ERS 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that both of the abstracts submitted for presentation at the European Respiratory Society International Congress 2022 in Barcelona on September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted for presentation.  NXP002 is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis.

Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: We believe NXP002 offers tremendous potential as a novel inhaled treatment for IPF and potentially other fibrosing interstitial lung diseases (“ILDs”).  The Company is progressing a pre-clinical programme to demonstrate how its proprietary new form of tranilast can down regulate fibrosis and inflammation following inhalation, whilst avoiding severe side effects, which are key issues in the treatment of IPF and other ILDs.  We are therefore delighted that the abstracts describing our initial work have been accepted following peer review.

“The ERS is a leading international respiratory congress.  It provides us the opportunity to share these positive data with the scientific and clinical communities and, very importantly, the congress is attended by all the major respiratory-focused pharmaceutical companies.  Ultimately, we will be looking to license NXP002 and the congress offers us an important opportunity to present and introduce NXP002 to potential licensing partners.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Nuformix plc

More articles like this

Nuformix plc

Nuformix lead programme introduced to major respiratory players (VIDEO)

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment

Nuformix plc

Nuformix introduces lead programme to major respiratory players

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment

Nuformix plc

Campaign calls for diagnosis of pulmonary fibrosis

The president of the Portuguese Society of Pulmonology, António Morais, warned that patients should not underestimate symptoms and insisted on the importance of early diagnosis in fibrotic diseases, stressing that it is crucial to stop progression. The campaign

Nuformix plc

Almost half of cancer deaths are preventable

Nearly 50% of cancer deaths worldwide are caused by preventable risk factors, such as smoking and drinking alcohol, according to the largest study of the link between cancer burden and risk factors1. Using estimates of cancer cases and

Nuformix plc

PF awareness means ‘Being here for each other’ in September

From sharing stories and “going blue,” to offering yoga sessions and hosting community walks, patients and supporters are set to mark Pulmonary Fibrosis Awareness Month, held annually in September. The effort is also aimed at raising research funds

Nuformix plc

What is cancer?

Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body.  Cancer can start almost anywhere in the human body, which is made up of trillions of cells.

Nuformix plc

Cancer warning signs

Cancer is the leading cause of death globally, the World Health Organisation says, killing almost 10 million people each year. While about one in six deaths are due to cancer, many forms of the disease can be cured if they

Nuformix plc

COVID-19 and IPF: Fundamental similarities found

An AI-guided analysis of more than 1000 human lung transcriptomic datasets found that COVID-19 resembles idiopathic pulmonary fibrosis (IPF) at a fundamental level, according to a study published July 20, 2022. In the aftermath of COVID-19, a significant number of

Nuformix plc

Nuformix progressing to robustly investigate NXP002’s efficacy

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that NXP002, a new form of tranilast and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis, has successfully

Nuformix plc

Nuformix to continue to optimise value from its existing assets

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the year ended 31 March 2022. Non-executive Directors’ Statement Introduction Following the departure of

Nuformix plc

Can you have both pulmonary fibrosis and emphysema together?

Combined pulmonary fibrosis and emphysema (CPFE) is a condition that causes symptoms of both pulmonary fibrosis and emphysema. People with CPFE have both air sac destruction (seen in people with emphysema) and also scarred lung tissue of what

Nuformix plc

Virtual, in-person events planned for 2022 PFF Walk

The Pulmonary Fibrosis Foundation (PFF) is hosting its sixth annual PFF Walk fundraiser with virtual and in-person events over the next few months to raise funds and awareness in support of people living with pulmonary fibrosis. “We encourage everyone to join

Nuformix plc

Beating cancer — the role of Europe’s environment

Cancer affects the lives of many Europeans. Environmental and occupational exposure to air pollution, radon, UV radiation, chemical carcinogens, asbestos and other risks contributes significantly to the high burden of cancer in Europe. However, all environmental and occupational

Nuformix plc

Living with pulmonary fibrosis

Pulmonary fibrosis is also a term that’s used to refer to a disease that is found in the interstitium of the lungs. It falls into an even larger group of diseases called ILDs. Why? Because the scarring is found in the interstitium of

Nuformix plc

Nuformix’s NXP004 has considerable commercial potential

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update in relation to the Company’s NXP004 programme, focused on the development of novel physical forms of

Nuformix plc

Most people believe in need for more cancer research

A new survey reveals the majority of the general public thinks more cancer research is in order, but many are reluctant to pitch in to the effort financially. Cancer touches nearly every person walking the planet, whether it

Nuformix plc

Nuformix to investigate a new formulation of NXP002

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update in relation to the Company’s NXP002 asset, a new form of tranilast and a potential novel inhaled treatment for Idiopathic

Nuformix plc

What are the symptoms of pulmonary fibrosis?

The different types of pulmonary fibrosis have similar symptoms. On this page we explain what they are. The main symptoms of pulmonary fibrosis are: breathlessness a cough that doesn’t go away feeling tired all the time clubbing of

No more posts to show